4.7 Article

An Nfil3-Zeb2-Id2 pathway imposes Irf8 enhancer switching during cDC1 development

期刊

NATURE IMMUNOLOGY
卷 20, 期 9, 页码 1174-+

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/s41590-019-0449-3

关键词

-

资金

  1. National Cancer Institute's Cancer Center Support grant [P30 CA91842]
  2. Institute of Clinical and Translational Sciences/Clinical and Translational Science Award from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [UL1TR000448]
  3. NIH Roadmap for Medical Research
  4. Howard Hughes Medical Institute
  5. National Science Foundation [DGE-1745038]
  6. US NIH [F30DK108498, K08 CA23188-01, P50-HG007735]
  7. Parker Institute for Cancer Immunotherapy
  8. Career Award for Medical Scientists from the Burroughs Wellcome Fund

向作者/读者索取更多资源

Classical type 1 dendritic cells (cDC1s) are required for antiviral and antitumor immunity, which necessitates an understanding of their development. Development of the cDC1 progenitor requires an E-protein-dependent enhancer located 41 kilobases downstream of the transcription start site of the transcription factor Irf8 (+41-kb Irf8 enhancer), but its maturation instead requires the Batf3-dependent +32-kb Irf8 enhancer. To understand this switch, we performed single-cell RNA sequencing of the common dendritic cell progenitor (CDP) and identified a cluster of cells that expressed transcription factors that influence cDC1 development, such as Nfil3, Id2 and Zeb2. Genetic epistasis among these factors revealed that Nfil3 expression is required for the transition from Zeb2(h)(i) and Id2(Io) CDPs to Zeb2(Io) and Id2(hi) CDPs, which represent the earliest committed cDC1 progenitors. This genetic circuit blocks E-protein activity to exclude plasmacytoid dendritic cell potential and explains the switch in Irf8 enhancer usage during cDC1 development.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据